Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869

Drugs in R and D

Volumn 5, Issue 3, 2004, Pages 176-181

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

APTA 2217; B 9302 107; BYK 20869; CORTICOSTEROID; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MUSCLE RELAXATION; NAUSEA; PATENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PSORIASIS; SINGLE DRUG DOSE; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DRUGS, INVESTIGATIONAL; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PHOSPHODIESTERASE INHIBITORS;

EID: 2942641713     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405030-00009     Document Type: Article

References (18)

1. ALTANA AG, Pharmacia Corporation. ALTANA and Pharmacia to collaborate in development and commercialization of respiratory disease product candidate. Media Release: 22 Apr 2002. Available from URL: http://www.altana.com
2. ALTANA AG, Tanabe Sciyaku Co Ltd. ALTANA and Tanabe Seiyaku sign Roflumilast cooperation in the Japanese Market. Media Release: 15 Nov 2002. Available from URL: http://www.altanapharma.com
3. ALTANA AG. ALTANA completes another phase III study on Roflumilast in COPD patients. Media Release: 10 Sep 2003. Available from URL: http://www.altanapharma.com
4. David M, Zech K, Seiberling M, et al. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability. Journal of Allergy and Clinical Immunology 113 (Suppl.): 220-1, No. 2, Feb 2004
5. Manegold A, Hauns B, David M, et al. Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500microg to 1000microg are dose-linear in healthy subjects. European Respiratory Journal Supplement 20 (Suppl. 38): 108 (plus poster), Sep 2002
6. Manegold A, Huennemayer A, Zech K, et al. Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects. European Respiratory Journal Supplement 20 (Suppl. 38): 109 (plus poster), Sep 2002
7. Drollmann A, Hartmann M, Zech K, et al. Patients with severe renal impairment do not require dose adjustment of roflumilast. European Respiratory Journal Supplement 20 (Suppl. 38): 108-9 (plus poster), Sep 2002
8. Timmer W, Leclerc V, Birraux G, et al. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks. American Journal of Respiratory and Critical Care Medicine 161 (Suppl.): 505 (plus poster), Part 2, Mar 2000
9. Leichtl S, Syed J, Bredenbröker D, et al. Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease. European Respiratory Journal Supplement 20 (Suppl. 38): 303 (plus poster), Sep 2002
10. ALTANA AG. RECORD Study shows new Roflumilast data in COPD patients. Media Release: 28 Sep 2003. Available from URL: http://www.altanapharma.com
11. Nell H, Louw C, Leichtl S, et al. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. American Journal of Respiratory and Critical Care Medicine 161 (Suppl.): 200, Part 2, Mar 2000
12. Hauns B, Leclerc V, Birraux G, et al. Four-week treatment with the new PDE4 inhibitor roflumilast in patients with exercise-induced asthma: safety, efficacy and inhibition of TNF-alpha ex vivo. European Respiratory Journal Supplement 16 (Suppl. 31): 540, Aug 2000
13. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. Journal of Clinical Pharmacology 42: 297-303, Mar 2002
14. Louw C, Williams Z, Leichtl S, et al. Roflumilast, a selective phosphodiesterase 4 inhibitor reduces late phase asthma and hyperresponsiveness. Respirology 7 (Suppl.): 22, Mar 2002
15. Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, et al. Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma. European Respiratory Journal Supplement 20 (Suppl. 38): 303 (plus poster), Sep 2002
16. van Schalkwyk EM, van Heerden K, Bredenbröker D, et al. Dose-dependent inhibitory effect of roflumilast, a new, orally active, selective phophodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction. European Respiratory Journal Supplement 20 (Suppl. 38): 110 (plus poster), Sep 2002
17. ALTANA Pharma. ALTANA Pharma Presents Studies of Roflumilast at the American Thoracic Society International Conference. Media Release: 21 May 2003. Available from URL: http://www.altanapharma.com
18. Altana AG. Additional Positive Roflumilast Data of RECORD Study at German Congress for Pneumonology. Media Release: 12 Mar 2004. Available from URL: http://www.altana.com